Efficient Passive Beta
Year-end funding pressures have begun to permeate through the prices for unfunded derivatives such as total return swaps and futures. For example, the price of going long S&P500 Total Return is 3m LIBOR + 40bps, far in excess of its long-term average of +20bps. With pricing so elevated, we look at choices available to those who want to invest in equities.
Futures pricing is also elevated
First, it’s important to remember that changes in the overall cost of funding affects both total return swaps and futures. It is easy to forget this given the cost of funding is visible in the price of a total return swap (via the funding leg). This is not the case for futures, where the implied funding is implicit in the basis to the cash market and the quarterly rolls of the contracts.
This chart shows the range of implied funding rates during quarterly rolls over recent years. The implied funding rate moves around during the two weeks when the roll is active, based on the value of the expiring contract and the next-nearest contract. A few things are clear:
- Futures implied funding and TRS pricing broadly move in line. The relationship is stronger for 3m swap pricing. This is expected, as the futures rolls themselves capture a 3m window (from the roll to the next quarterly futures expiry)
- While swap pricing is quite elevated currently relative to history, so is implied futures pricing. The increase in the cost of funding has affected both instruments. As such, it is simply not a case of trading futures because swaps are too expensive.
- Futures pricing in the roll can highly variable, and the cost of funding in subsequent rolls is unknown today.
One way around this dilemma is to pursue a fully funded alternative. This might be an ETF whose management fees and tracking error are low compared to the currently high funding rates in swaps and futures. However, this requires access to cash equal to the desired notional exposure.
Another way to access beta is through options. Unlike futures and swaps, current option pricing works in favour of those looking to go long. This is due to significant increases in skew over the past year, which has made the price of downside put options more expensive relative to upside call options. This offers cheap entry points for beta-like strategies.
For example, in S&P 500 it is currently near zero-cost to sell a 3-month 90% put option and buy a 3-month 104% call option – a combination known as a risk-reversal. This provides a buffer on the downside of 10%, but only a 4% hurdle on the upside until the option becomes in-the-money. This asymmetry is appealing for those looking for cheap upside exposure. This chart shows the scenario analysis of this strategy at trade date and at maturity.
When looking at gaining the most efficient exposure to equities, it is important to consider all the alternatives and weigh the pros and cons of each. At the moment, the overall cost of funding has increased pricing on total return swaps and futures but at the same time, the option market dynamics have made it historically inexpensive to use options to get equity exposure. In a lower expected return world, finding free outperformance through efficient implementation can provide a little bit of extra return for the overall portfolio.
The Solutions Team
The Solutions team provides derivative overlay and risk management fiduciary services to Asset Owners and Managers in Australia. Our goal is to provide asset owners and managers with an experienced overlay advisory and execution service to improve portfolio outcomes and cost efficiency.
Financial services provided by Challenger Investment Solutions Management Pty Ltd (ABN 63 130 035 353 AFSL 487354) (CIP Asset Management, CIPAM). The material in this document is general background information about Challenger’s Investment Solutions activities and is current at the date of this document. It is information given in summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These individual circumstances should be considered with professional advice when deciding if an investment is appropriate. Nothing in this document should be considered a solicitation, offer or invitation to buy, subscribe or sell any, or a recommendation of, financial products. All reasonable care has been taken to ensure that the facts stated and opinions given in this document are fair and accurate. To the maximum extent permitted by law, the recipient releases each member of the Challenger Limited group of companies, their directors, officers, employees, representatives and advisers from any liability (including, without limitation, in respect of direct, indirect or consequential loss or damage or loss or damage arising by negligence) arising in relation to any recipient relying on anything contained in or omitted from this document. Any forward looking statements included in this presentation involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, Challenger. In particular, they speak only as of the date of these materials, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from forward looking statements and assumptions on which those statements are based. Given these uncertainties, recipients are cautioned not to place undue reliance on such forward looking statements. Any past performance information provided in this presentation is not a reliable indication of future performance. This document is not audited.